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S1. Methods 
Procedures. TBC1D24 variants were identified through a variety of methods, 
including whole exome sequencing and Sanger validation (patients #4, #6a, #7a-c, #9, 
#12a, #13, #16, #19, #20a, #21, #22, #23a, #26, #27), Sanger sequencing (patients 
#1a-h, #6b, #8a-b, #12b, #14, #20b, #23b, #24, #25, #28, #29, #30), next-generation 
sequencing panels (patients #2, #3, #15, #17a-b, #18, #21) and multipoint linkage 
analysis followed by targeted sequence enrichment and massively parallel sequencing 
(patients 5#a-d). The longest TBC1D24 isoform, harbouring exon 3, was referenced 
(isoform 1, NM_001199107.1, GRCh37/hg19). Forty-seven patients had biallelic 
mutations. In only one patient (#24) was a mutation not identified in the second allele. 
For this patient, real-time PCR of genomic DNA for all coding exons was performed 
to detect a deletion or insertion of a whole exon, and the last intron was sequenced. 
None of these procedures identified a second mutation. The other mutation for this 
patient is probably in the promoter or in a deep intronic region, affecting, for example, 
a branch site. We did not perform further tests to explore this, since there was no 
clinical doubt regarding the diagnosis of DOORS syndrome. 
 
Bioinformatics. TBC1D24 sequences from H. sapiens, M. musculus, R. norvegicus 
and D. melanogaster Sky, and sequences from seven other insect Sky proteins were 
selected as the positive set, then compared to a discriminative set of TBC-domain 
proteins, consisting of human and mouse TBC1D1 and TBC1D7. E-values and p-
values were calculated. E-values estimate the likelihood of a conserved motif based 
on all input sequences against the amino acid composition background of the input 
(Sky/TBC1D24 sequence), whereas p-values estimate the probability of conservation 
for each protein and motif. 
 
In vitro modelling. Cortical cells from wild-type C57BL/6J P1 mouse pups were 
prepared and cultured as previously described.e1 2 x 106 cells were electroporated 
with 1.5 μg of each DNA construct by nucleofection (Amaxa). Cells were cultured 
for 4 days before fixation with 4% paraformaldehyde and staining with rat anti-HA 
(Roche) overnight at 4oC. Transfected cells were visualized using an anti-rat Alexa 
459 secondary antibody (Life Technologies) and images were taken under 
fluorescence (Leica). A minimum of 60 neurites from transfected neurons 
representing each construct were measured using Image-J software (NIH). Human 
wild-type TBC1D24 was generated by RT-PCR, adding an in-frame C-terminal HA-
tag, followed by cloning into pcDNA3.1 (Invitrogen). TBC1D24 mutants were 
generated by site-directed mutagenesis and were sequenced prior to cloning. 
 
 
 
 
 
 
 
 
 
 
 
Table e-1. Details of the epilepsy phenotype and mutations identified in TBC1D24. Longest isoform, harbouring exon 3, is used 
(isoform 1, NM_001199107.1, hg19). 
Patient 
number/ 
gender, 
current 
age* 
Age at 
seizure 
onset 
Seizure types 
and 
frequency 
Details of Mc or 
clonic seizures, if 
present 
Syndrome 
classification 
Current 
AEDs 
AEDs 
previously 
tried 
Epilepsy outcome/ 
clinical evolution 
Alleles, DNA 
(protein) 
1a/ W, 54 
years 
 
4 
months 
GTC, 
occasional 
(12-16 years); 
Mc, weekly to 
monthly (4-12 
years) 
in childhood, 
spontaneous, erratic, 
bilateral, or massive, 
isolated or in clusters, 
could last for many 
hours, sometimes 
evolving into GTC; in 
youth, segmental, 
familial 
infantile 
myoclonic 
VPA none 
still sporadic Mc, 
free from GTC 
chr16:2546588G>C 
(p.Asp147His)/ 
chr16:2550823C>T 
(p.Ala515Val) 
precipitated by fatigue/ 
drowsiness, acoustic/ 
light stimuli, repetitive 
movements 
1b/ W, 52 
years 
7 
months 
GTC, 
occasional 
(12-16 years); 
Mc, weekly to 
monthly (4-12 
years) 
in childhood, 
spontaneous, erratic, 
bilateral, or massive, 
isolated or in clusters, 
could last for many 
hours, sometimes 
evolving into GTC; in 
youth, segmental, 
precipitated by fatigue/ 
drowsiness, acoustic/ 
light stimuli, repetitive 
movements 
familial 
infantile 
myoclonic 
PB PHT 
still sporadic Mc, 
free from GTC 
chr16:2546588G>C 
(p.Asp147His)/ 
chr16:2550823C>T 
(p.Ala515Val) 
1c/ M, 50 
years 
5 
months 
GTC, 
occasional 
(12-16 years); 
Mc, weekly to 
monthly (4-12 
years) 
in childhood, 
spontaneous, erratic, 
bilateral, or massive, 
isolated or in clusters, 
could last for many 
hours, sometimes 
evolving into GTC; in 
youth, segmental, 
precipitated by fatigue/ 
drowsiness, acoustic/ 
light stimuli, repetitive 
movements 
familial 
infantile 
myoclonic 
PB PHT 
still sporadic Mc, 
free from GTC 
chr16:2546588G>C 
(p.Asp147His)/ 
chr16:2550823C>T 
(p.Ala515Val) 
1d/ M, 47 
years 
5 
months 
GTC, 
occasional 
(12-16 years); 
Mc, weekly to 
in childhood, 
spontaneous, erratic, 
bilateral, or massive, 
isolated or in clusters, 
familial 
infantile 
myoclonic 
PB PHT 
still sporadic Mc, 
free from GTC 
chr16:2546588G>C 
(p.Asp147His)/ 
chr16:2550823C>T 
(p.Ala515Val) 
monthly (4-12 
years) 
could last for many 
hours, sometimes 
evolving into GTC; in 
youth, segmental, 
precipitated by fatigue/ 
drowsiness, acoustic/ 
light stimuli, repetitive 
movements 
1e/ W, 43 
years 
36 
months 
GTC, 
occasional 
(12-16 years); 
Mc, weekly to 
monthly (4-12 
years) 
in childhood, 
spontaneous, erratic, 
bilateral, or massive, 
isolated or in clusters, 
could last for many 
hours, sometimes 
evolving into GTC; in 
youth, segmental, 
familial 
infantile 
myoclonic 
VPA CBZ, PB 
still sporadic Mc, 
free from GTC 
chr16:2546588G>C 
(p.Asp147His)/ 
chr16:2550823C>T 
(p.Ala515Val) 
precipitated by fatigue/ 
drowsiness, acoustic/ 
light stimuli, repetitive 
movements 
1f/ M, 59 
years 
16 
months 
GTC, 
occasional 
(12-16 years); 
Mc, weekly to 
monthly (4-12 
years) 
in childhood, 
spontaneous, erratic, 
bilateral, or massive, 
isolated or in clusters, 
could last for many 
hours, sometimes 
evolving into GTC; in 
youth, segmental, 
precipitated by fatigue/ 
drowsiness, acoustic/ 
light stimuli, repetitive 
movements 
familial 
infantile 
myoclonic 
none none 
Mc triggered by 
repetitive 
movements or 
fatigue; sporadic 
GTC (every 2-3 
years) 
chr16:2546588G>C 
(p.Asp147His)/ 
chr16:2550823C>T 
(p.Ala515Val) 
1g/ M, 58 
years 
12 
months 
GTC, 
occasional 
(12-16 years); 
Mc, weekly to 
monthly (4-12 
years) 
in childhood, 
spontaneous, erratic, 
bilateral, or massive, 
isolated or in clusters, 
could last for many 
hours, sometimes 
evolving into GTC; in 
youth, segmental, 
precipitated by fatigue/ 
drowsiness, acoustic/ 
light stimuli, repetitive 
movements 
familial 
infantile 
myoclonic 
none none 
Mc triggered by 
repetitive 
movements or 
fatigue; sporadic 
GTC (every 2-3 
years) 
chr16:2546588G>C 
(p.Asp147His)/ 
chr16:2550823C>T 
(p.Ala515Val) 
1h/ M, 56 
years 
12 
months 
GTC, 
occasional 
(12-16 years); 
Mc, weekly to 
in childhood, 
spontaneous, erratic, 
bilateral, or massive, 
isolated or in clusters, 
familial 
infantile 
myoclonic 
none VPA 
Mc triggered by 
repetitive 
movements or 
fatigue; sporadic 
chr16:2546588G>C 
(p.Asp147His)/ 
chr16:2550823C>T 
(p.Ala515Val) 
monthly (4-12 
years) 
could last for many 
hours, sometimes 
evolving into GTC; in 
youth, segmental, 
precipitated by fatigue/ 
drowsiness, acoustic/ 
light stimuli, repetitive 
movements 
GTC (every 2-3 
years) 
2/ W, 5 
months 
3.5 
months 
focal (motor), 
weekly; 
clonic, 
weekly; 
episodes of lip 
quivering with 
no EEG 
not present focal 
LEV, 
LTG 
none drug-resistant 
chr16:2547068A>G 
(p.Asn307Asp)/ 
chr16:2546994C>G 
(p.Pro282Arg) 
correlate, 
weekly 
3/ M, 2 
years 
3 
months 
GTC, rare; 
Mc, daily 
involving peri-oral 
region and/or limbs, 
rhythmic, bilateral, 
lasting up to 30 
minutes, no loss of 
consciousness 
infantile 
myoclonic 
 
CLB, 
STP, VPA 
PB 
with STP complete 
control of GTC, 
moderate control 
of Mc 
chr16:2546835T>C 
(p.Phe229Ser)/ 
chr16:2550465C>T 
(p.Ala500Val) 
4/ W, 15 
years 
36 
hours 
GTC, 
monthly; Mc, 
daily; tonic, 
daily 
prolonged, continuous 
runs of spontaneous 
Mc, both at rest and on 
maintaining posture; 
involving tongue, peri-
ocular region, lower 
limbs, head and trunk; 
not markedly worsened 
progressive 
myoclonic 
CBZ, 
VPA 
CLZ, LEV, PIR, 
prednisolone, 
TPM 
rarer GTCs (<1 / 
month); Mc daily; 
tonic seizures 
ceased at 7 years; 
progressive clinical 
deterioration 
(see Video 1) 
chr16:2548334G>T 
(p.Arg360Leu)/ 
chr16:2548334G>T 
(p.Arg360Leu) 
by action; could result 
in falls, unable to feed 
self; precipitated by 
constipation, delayed 
medication or tiredness 
5a/ M, 46 
years 
2 
months 
focal 
(prominent 
eye blinking, 
facial and limb 
jerking), 
weekly; GTC, 
weekly 
not present focal 
CBZ, 
CLZ, PB 
none 
ongoing seizures, 
usually due to non-
compliance 
chr16:2546900T>C 
(p.Phe251Leu)/ 
chr16:2546900T>C 
(p.Phe251Leu) 
5b/ M, 40 
years 
2 
months 
focal 
(prominent 
eye blinking, 
facial and limb 
not present focal 
PB, PHT, 
VPA 
none 
rare seizures 
continue despite 
medication 
chr16:2546900T>C 
(p.Phe251Leu)/ 
chr16:2546900T>C 
(p.Phe251Leu) 
jerking and 
dyscognitive), 
unknown 
initial 
frequency 
5c/ W, 33 
years 
2 
months 
focal 
(prominent 
eye blinking, 
facial and limb 
jerking), 
weekly 
not present focal 
CBZ, 
LTG 
VPA 
controlled on 
medication 
chr16:2546900T>C 
(p.Phe251Leu)/ 
chr16:2546900T>C 
(p.Phe251Leu) 
5d/ M, 29 
years 
2 
months 
focal 
(prominent 
eye blinking, 
facial and limb 
jerking and 
not present focal 
CBZ, 
PHT, 
VPA 
none 
controlled on 
medication 
chr16:2546900T>C 
(p.Phe251Leu)/ 
chr16:2546900T>C 
(p.Phe251Leu) 
dyscognitive), 
weekly 
 
6a/ W, 
deceased 
 
5 
weeks 
migrating 
clonic, focal 
(lateral 
deviation of 
the head and 
eyes, twitches 
of the eyelids, 
flushing or 
cyanosis of the 
face; or subtle 
seizures with 
cyanosis and 
movement 
arrest), daily 
initially discontinuous, 
then continuous lasting 
several hours, 
migrating from one 
limb to another; no 
obvious triggers 
 
epilepsy of 
infancy with 
migrating focal 
seizures 
(EIMFS) 
 
deceased 
 
CBZ, CLB, 
CLZ, KD, PB, 
PHT, ZNS 
 
drug-resistant, 
death as probable 
consequence of 
chronic respiratory 
failure at 8 years 
chr16:2546617C>A 
(p.Cys156*)/ 
chr16:2546835T>C 
(p.Phe229Ser) 
(initial phase), 
almost 
permanent 
(stormy 
phase), 
clusters of 
several 
seizures per 
hour (late 
phase) 
6b/ W, 
deceased 
4 
weeks 
migrating 
clonic, focal 
(lateral 
deviation of 
the head and 
eyes, twitches 
initially discontinuous, 
then continuous lasting 
several hours, 
migrating from one 
limb to another; no 
obvious triggers 
epilepsy of 
infancy with 
migrating focal 
seizures 
(EIMFS) 
deceased 
CBZ, CLB, 
CLZ, KD, PB, 
PHT, ZNS 
drug-resistant, 
death (probable 
SUDEP) at 18 
months 
chr16:2546617C>A 
(p.Cys156*)/ 
chr16:2546835T>C 
(p.Phe229Ser) 
of the eyelids, 
flushing or 
cyanosis of the 
face; or subtle 
seizures with 
cyanosis and 
movement 
arrest), daily 
(initial phase) 
almost 
permanent 
(stormy 
phase), 
clusters of 
several 
seizures per 
hour (late 
phase) (see 
Video 2) 
7a/ M, 
deceased 
2 
months 
clonic, Mc, 
unknown 
initial 
frequency 
erratic, segmental, 
multifocal, unilateral, 
migrating or alternating 
pseudo-rhythmic, 
affecting eye and peri-
oral region, startle 
responses to auditory 
and tactile stimuli, 
duration increasing 
with age (up to 5-6 
days), infrequent 
rhythmic clonic 
seizures 
early-onset 
epileptic 
encephalopathy 
deceased 
CLB, CLZ, PB, 
TPM, VGB 
VPA 
drug-resistant; 
death due to an 
infection (3.5 
years) 
chr16:2547714-
2547715delGT 
(p.Ser324Thrfs*3)/ 
chr16:2547714-
2547715delGT 
(p.Ser324Thrfs*3) 
7b/ W, 
deceased 
3 
weeks 
focal 
(prolonged 
staring 
episodes 
associated 
with a general 
increase in 
muscle tonus 
and frightened 
facial 
expression, or 
aversion of the 
head and eyes 
to either side), 
Mc, unknown 
segmental, multifocal, 
unilateral, or 
generalised,  pseudo-
rhythmic, involving 
face and limbs, 
alternating and 
migrating, never 
occurring in sleep  
early-onset 
epileptic 
encephalopathy 
deceased na 
drug-resistant; 
death during status 
epilepticus 
associated with 
pulmonary 
infection 
(3.5 years) 
chr16:2547714-
2547715delGT 
(p.Ser324Thrfs*3)/ 
chr16:2547714-
2547715delGT 
(p.Ser324Thrfs*3) 
initial 
frequency 
7c/ M, 
deceased 
first 
month 
of life 
focal (gaze 
deviation), 
Mc, spasms, 
unknown 
initial 
frequency 
na 
early-onset 
epileptic 
encephalopathy 
deceased na 
drug-resistant; 
death due to 
pulmonary 
infection 
(6.5 years) 
chr16:2547714-
2547715delGT 
(p.Ser324Thrfs*3)/ 
chr16:2547714-
2547715delGT 
(p.Ser324Thrfs*3) 
8a/ M, 10 
years 
24 
hours 
of life 
Mc, daily, in 
clusters 
involving face and 
eyelids, sometimes 
extending to the limbs 
or the whole body;   
triggers: acoustic 
stimuli; 
partially controlled 
with PHT 
familial 
infantile 
myoclonic 
CLZ, 
LEV, 
PHT, 
TPM 
CBZ, LTG, PB, 
VPA 
drug-resistant (Mc 
weekly) 
chr16:2546606G>A 
(p.Glu153Lys)/ 
chr16:2546606G>A 
(p.Glu153Lys) 
8b/ M, 3.5 
years 
2.5 
months 
Mc, in 
clusters, 
seizure-free 
intervals<15 
days 
long-lasting, segmental 
or generalized, variable 
topography, involving 
eyelids, peri-oral 
region, or the whole 
face, without loss of 
consciousness;  
triggers: feeding (facial 
Mc), febrile episodes; 
partially controlled 
with PHT 
familial 
infantile 
myoclonic 
CLZ, PHT na drug-resistant 
chr16:2546606G>A 
(p.Glu153Lys)/ 
chr16:2546606G>A 
(p.Glu153Lys) 
9/ W, 3 
years 
first 
day of 
life 
focal, Mc, 
tonic, daily, in 
clusters 
segmental or 
generalised, variable 
topography, involving 
eyelids, peri-oral 
early-onset 
epileptic 
encephalopathy 
CLZ, KD, 
PIR, ZNS 
CLB, CBZ, 
LEV, LTG, PB, 
PHT, TPM, 
VPA 
drug-resistant (Mc 
daily) 
chr16:2546426C>T 
(p.Pro93Ser)/ 
chr16:2550823C>T 
(p.Ala515Val) 
region, or the whole 
face 
10/ W, 1 
year 
2 
months 
clonic, Mc, 
sGTC, 
monthly 
triggered by fever 
early-onset 
epileptic 
encephalopathy 
hydrocorti
sone, 
LEV, PB, 
VPA 
none 
drug-resistant (Mc 
daily, clonic and 
sGTCs monthly) 
chr16:2546181A>G 
(p.Asp11Gly)/ 
chr16:2546181A>G 
(p.Asp11Gly) 
11/ M, 8.5 
years 
7 
months 
Mc, twice a 
month 
alternatively affecting 
eyelids, either the right 
or left limbs, 
sometimes all four 
limbs or the trunk, 
lasting from several 
hours to up to 2 weeks, 
mostly disappearing 
during sleep, no loss of 
consciousness, 
infantile 
myoclonic 
TPM 
BDZs, CBZ, 
LEV, PB, VPA, 
ZNS 
good response to 
TPM 
(3 month seizure-
free period 
and now minor Mc 
triggered by fever) 
chr16:2546958G>A 
(p.Arg270His)/ 
chr16:2546958G>A 
(p.Arg270His) 
triggered by fever or 
fatigue 
12a/ W, 7 
years 
15 
months 
focal (motor), 
sGTC, weekly 
not present focal 
LEV, 
OXC, 
ZNS 
none 
>90% reduction in 
frequency on ZNS 
chr16:2546264G>C 
(p.Ala39Pro)/  
chr16:2550940-
2550946del 
(p.Gln554Leufs*12) 
12b/ W, 
13 years 
8 
months 
focal (motor), 
sGTC, weekly 
not present focal 
LEV, 
ZNS 
OXC 
>90% reduction in 
frequency on ZNS 
chr16:2546264G>C 
(p.Ala39Pro)/  
chr16:2550940-
2550946del 
(p.Gln554Leufs*12) 
13/ W, 12 
years 
2 
months 
focal (eye 
deviation to 
the left, staring 
gaze, limb 
not present 
early-onset 
epileptic 
encephalopathy 
CZP, 
FBM, PB 
CBZ, KD, LEV, 
OXC, PHT, 
PRM, TPM 
drug-resistant 
chr16:2546880C>T 
(p.Ala244Val)/ 
chr16:2546880C>T 
(p.Ala244Val) 
posturing), 
GTC, daily 
14/ M, 14 
years 
3 
months 
clonic, focal 
(multiple types 
including 
dyscognitive), 
sGTC, daily 
na multifocal 
CLZ, 
TPM, 
VPA 
CLB, LTG 
drug-resistant, 
clinical 
deterioration 
chr16:2546828C>T 
(p.Arg227Trp)/ 
chr16:2550823C>T 
(p.Ala515Val) 
15/ M, 8 
years 
7 
months 
focal, Mc, 
sGTC, 
monthly 
segmental, involving 
right or left hand, 
tongue or other facial 
parts 
focal 
OXC, 
SUL 
AZM, CBZ, 
LEV, LTG, 
TPM 
VPA, ZNS 
free of sGTC, 
occasional Mc 
chr16:2546682C>G 
(p.Ser178Trp)/ 
chr16:2546829G>A 
(p.Arg227Gln) 
16/ M, 9.5 
years 
5 
months 
GTC, weekly not present unclassified 
VPA, 
CLB 
LTG 
drug-resistant, 
daily GTC 
chr16:2547106G>C 
(p.Lys319Asn)/ 
chr16:2547106G>C 
(p.Lys319Asn) 
17a/ W, 
deceased 
45 
minute
s after 
birth 
clonic, Mc 
(mostly), 
spasms, tonic, 
daily, longest 
remission for 2 
months 
multifocal Mc, 
involving peri-oral 
region (and other facial 
parts) and limbs 
early-onset 
epileptic 
encephalopathy 
deceased 
CLB, ESM, 
LEV, LTG, 
OXC, PB, PHT, 
TPM, VGB, 
VPA, ZNS, 
VPA 
drug-resistant 
epilepsy, 
predominant Mc; 
died at the age of 
20 months due to 
respiratory failure 
following 
respiratory 
infection 
chr16:2548263delT 
(p.His336Glnfs*12)/ 
chr16:2546181A>G 
(p.Asp11Gly) 
17b/ M, 
deceased 
20 
minute
s after 
birth 
clonic, Mc 
(mostly), 
tonic, daily 
after neonatal 
period until 13 
months 
multifocal, erratic, Mc, 
involving face 
(prominent eye 
twitching) and limbs 
early-onset 
epileptic 
encephalopathy 
deceased 
CLB, ESM, 
LEV, LTG, 
OXC, PB, PHT, 
TPM 
on continuous 
thiopental infusion 
after 13 months; 
died at the age of 
24 months due to 
respiratory failure 
following 
chr16:2548263delT 
(p.His336Glnfs*12)/ 
chr16:2546181A>G 
(p.Asp11Gly) 
respiratory 
infection 
18/ M, 11 
years 
7 
months 
Mc, sGTC, 
weekly 
triggered by fever and 
fatigue, sometimes 
evolving into 
prolonged GTC 
infantile 
myoclonic 
CLZ, PIR, 
VPA 
CLB, LEV, 
LTG, TPM 
drug-resistant 
(frequent Mc, 
sometimes 
evolving into 
sGTCs, usually 
prolonged) 
chr16:2546768C>T 
(p.Gln207*)/ 
chr16:2550809A>G 
(splice-site) 
19/ M, 21 
years 
2 
months 
focal, sGTC, 
weekly 
not present focal 
CBZ, 
CLZ 
CLB, PB, TPM, 
STP VPA, ZNS 
drug-resistant 
chr16:2546873C>T 
(p.Arg242Cys)/ 
chr16:2546267C>T 
(p.Arg40Cys) 
20a/ M, 
15 years 
6 
months 
focal, 
unknown 
not present unclassified na na 
good control with 
LAC, LTG, TPM 
chr16:2546873C>T 
(p.Arg242Cys)/ 
initial 
frequency 
chr16:2546873C>T 
(p.Arg242Cys) 
20b/ M, 8 
years 
4 
months 
focal, 
unknown 
initial 
frequency 
not present unclassified na na 
good control with 
CZP, LAC, TPM 
chr16:2546873C>T 
(p.Arg242Cys)/ 
chr16:2546873C>T 
(p.Arg242Cys) 
21/ W, 3 
years 
6 
weeks 
focal, sGTC, 
daily 
not present focal na 
CLB, cortisone 
pulses, CLZ, 
DZP, LEV, 
LTG, MDZ, 
OXC, PB, 
SUL,VPA, ZNS 
drug-resistant 
chr16:2548263delT 
(p.His336Glnfs*12)/ 
chr16:2549421+5G>A 
(splice-site) 
22/ M, 6 
years 
7 
months 
clonic, focal, 
sGTC, weekly 
na focal 
CBZ, 
CLB, 
VPA 
none drug-resistant 
chr16:2546873C>T 
(p.Arg242Cys)/ 
chr16:2546873C>T 
(p.Arg242Cys) 
23a/ M, 9 
years 
3 
months 
focal, Mc, 
weekly 
na myoclonic 
CLB, 
LTG, 
VPA 
CLZ, LEV, PB, 
TPM 
after initial control 
on PB and CLB, at 
the age of 11.5 
years clinical 
deterioration with 
daily seizures and 
encephalopathy; 
very frequent Mc 
persisted after 
recovery (see 
Video 3) 
chr16:2546207C>T 
(p.Gln20*)/ 
chr16:2546873C>T 
(p.Arg242Cys) 
23b/ M, 1 
year 
3 
months 
focal and Mc, 
frequently; 
sGTC, two-
three times per 
year 
na myoclonic 
CLB, 
LEV, 
TPM 
none 
drug-resistant (see 
Video 4) 
chr16:2546207C>T 
(p.Gln20*)/ 
chr16:2546873C>T 
(p.Arg242Cys) 
24/ W, 5 
years 
3 
months 
clonic and Mc, 
weekly; focal 
and GTC, 
monthly 
prolonged (several 
hours), erratic, 
involving one segment 
of a limb; no alteration 
of consciousness; 
triggered by fever 
familial 
infantile 
myoclonic 
CLZ, 
VPA 
CBZ, LEV, 
STP, TPM 
drug-resistant 
(prolonged Mc 
daily; clonic 
seizures monthly, 
requiring BDZ 
injection, see 
Video 5) 
chr16:2548263delT 
(p.His336Glnfs*12)/ 
? 
25/ M, 22 
years 
7 
months 
absences, 
GTC, spasms, 
unknown 
initial 
frequency 
not present generalised 
CLB, 
PHT 
CBZ 
seizure-free >12 
months on CLB 
and PHT 
chr16:2546873C>T 
(p.Arg242Cys)/ 
chr16:2546873C>T 
(p.Arg242Cys) 
26/ W, 
deceased 
first 
day of 
life 
focal, Mc, 
daily 
na 
early-onset 
epileptic 
encephalopathy 
deceased PB 
drug-resistant, died 
at age of 6 months 
chr16:2546268G>T 
(p.Arg40Leu)/ 
chr16:2546268G>T 
(p.Arg40Leu) 
27/ M, 4 
years 
9 
weeks 
focal, GTC, 
Mc, tonic, 
daily 
spontaneous, no 
obvious triggers 
infantile 
myoclonic 
LTG, PB, 
TPM 
 
LEV, 
prednisolone, 
VPA 
drug-resistant, 
currently Mc and 
tonic seizures 
weekly 
chr16:2546477G>A 
(p.Gly110Ser)/ 
chr16:2548254G>T 
(p.Leu333Phe) 
28/ W, 
deceased 
first 
day of 
life 
focal (multiple 
types), 
spasms, 
frequency 
ranged from 
daily to 
monthly 
not present 
early-onset 
epileptic 
encephalopathy 
deceased 
CLZ, KD, LAC, 
LEV, MDZ, 
OXC, PB, PHT, 
steroids, TPM, 
VGB 
drug-resistant 
epilepsy; died at 10 
months 
chr16:2550426dupA 
(p.His487Glnfs*71)/ 
chr16:2546462T>C 
(p.Cys105Arg) 
29/ W, 27 
years 
8 years 
GTC, initially 
sporadically, 
since the age 
of 15 years 
monthly 
not present generalised 
LTG, 
OXC, 
PRM 
LEV, TPM, 
VPA 
drug-resistant 
chr16:2546768C>T 
(p.Gln207*)/ 
chr16:2548381G>C 
(p.Gly376Arg) 
30/ M, 7 
years 
1 week 
focal 
(prolonged 
stiffening with 
eye and head 
deviation to 
one side), 
Mc, sGTC, 
daily 
na focal na 
CLB, PB, TPM, 
VPA 
drug-resistant 
chr16:2550350del 
(p.Glu462Serfs*61)/ 
chr16:2550350del 
(p.Glu462Serfs*61) 
31/ W, 9 
years 
6 years 
focal (gazing, 
cyanosis, 
cramping of 
left hand, 
tremor, 
atonia), GTC, 
sGTC, daily, 
not present unclassified 
LTG, 
VPA 
dexamethasone 
pulses, LEV, 
OXC, TPM, 
VGB 
drug-resistant 
(weekly seizure 
frequency at last 
follow-up) 
chr16:2546328G>A 
(p.Arg60Gln)/ 
chr16:2546851G>A 
(p.=); in cis 
 The patients are ordered as follows: patients with normal cognitive function (#1a-b-2); patients with intellectual disability but no other DOORS 
features (#3-13); patients with intellectual disability and acral manifestations (#14-16); patients with intellectual disability and hearing impairment 
(#17a-b-18); patients with DOORS syndrome (#19-30); patients where a clear association of the clinical phenotype with changes in TBC1D24 could 
not be established (#31-32). 
*Age is on January 2015. 
Videos 1-5 are in Supplemental data.  
All mutations were validated by Sanger sequencing. 
initially in 
clusters 
32/ M, 13 
years 
3 years 
absence, 
atonic, GTC, 
Mc, daily 
spontaneous, 
unprovoked by 
triggers, previous 
reports of trigger by 
light but not 
documented 
epilepsy with 
myoclonic 
atonic seizures 
FBM, 
RFM, 
VNS 
AZM, CLB, 
CLZ, ESM, KD, 
LEV, LTG, 
prednisolone, 
VPA 
drug-resistant 
16p13.3 duplication of 
407 Kb including, but 
not interrupting 
TBC1D24 (2,481,289-
2,888,632)x3 
*The histidine (His) at position 336 is substituted by a glutamine (Gln), which is followed by a frameshifted protein sequence (fs) ending with a 
termination codon (Ter) after 12 non-native aminoacids. 
? In patient #24, no mutation was identified in the second allele.  
The following patients have been reported to some degree previously: #1a-h (de Falco et al., 2001), #4 (Muona et al., 2014), #5a-d (Corbett et al., 
2010), 6a-b (Milh et al., 2010), #7a-c (Güven et al., 2013), #8a-b (Poulat et al., 2015), #11(Doummar et al, 2015), #12a-b(Cardon & Holder, 2015), 
#17a-b(Gnidovec Stražišar et al., 2015), #19-27 (Campeau et al., 2014a), #29 (Bilo et al., 2014). 
 
AEDs=anti-epileptic drugs; na=data not available; AZM=acetazolamide; BDZ=benzodiazepine; CBZ=carbamazepine; CLB=clobazam; 
CLZ=clonazepam; CZP= clorazepate; DZP=diazepam; ESM=ethosuximide; FBM=felbamate; GBP=gabapentin; KD=ketogenic diet; 
LEV=levetiracetam; LTG=lamotrigine; MDZ=midazolam; OXC=oxcarbazepine; PB=phenobarbital; PGB=pregabalin; PIR=piracetam; 
PHT=phenytoin; PRM=primidone; RFM=rufinamide; STP=stiripentol; SUL=sulthiame; TPM=topiramate; VGB=vigabatrin; VNS= vagus nerve 
stimulator; VPA=sodium valproate; ZNS=zonisamide; W=woman; M=man; GTC= tonic-clonic seizures without apparent focal onset; sGTC=tonic-
clonic seizures with apparent focal onset; Mc=myoclonic seizures; SE=status epilepticus.
Table e-2. EEG and neuroimaging results.  
Patient 
number 
EEG 
Photoparoxysmal 
response 
Neuroimaging 
1a normal (age 12 years) not present na 
1b generalized spike and wave; (age 14 years)  yes, Waltz type IV  normal (age 39 years) 
1c normal (age 28 years) not present normal (age 32 years) 
1d normal (age 18 years) not present normal (age 20 years) 
1e normal (age 37 years) not present normal (age 38 years) 
1f normal (age 18 years) not present na 
1g left temporal abnormalities (age 19 years)  not present na 
1h normal background activity (age 15 years) yes, Waltz type II-III na 
2 
frontal abnormalities; one focal seizure without 
alteration of consciousness was recorded, with 
probable left hemispheric onset 
not present normal 
3 normal not present normal 
 4 
 
focal interictal epileptiform activity (at 5 months); 
focal epileptiform activity and bilaterally 
synchronous posterior quadrant fast spike and slow 
wave discharges, myoclonic jerks without 
correlated epileptiform discharges (at 16 months); 
generalised slowing and focal epileptiform 
discharges (at 2 years); focal slowing (at 3 and 5 
years); intermittent bilaterally synchronous and 
independent spike-slow wave and polyspike-slow 
wave discharges, most prominent during early 
sleep (at 8 years); generalised epileptiform 
discharges increasing in sleep (at 9 years); 
generalised slowing and epileptiform discharges 
and frequent focal discharges, more frequent in 
sleep, no obvious EEG correlate with myoclonic 
not present 
cerebellar atrophy, right hippocampal sclerosis (at 14 
years) 
jerks (at 11 years); interictal generalised spike 
wave and polyspike wave activity (at 15 years) 
5a na not present na 
5b 
6-7 Hz low amplitude background; no paroxysmal 
activity (at 31 years) 
not present na 
5c 
irregular background 7-11 Hz; bitemporal high 
amplitude theta; no epileptiform activity (at 24 
years) 
not present 
right hippocampal sclerosis; cerebellar atrophy (at 28 
years) 
5d 
irregular background 6-9 Hz; some paroxysmal 
slow and sharp; no definite epileptiform activity (at 
20 years) 
not present cerebellar atrophy (at 21 years) 
 
6a 
 
first interictal: slow background activity, with slow 
waves, rare paroxysmal activity; interictal stormy 
phase: multifocal spikes, slow background activity; 
ictal: focal theta discharge followed by delta large 
amplitude hemispheric discharge; interictal late 
na 
birth: no structural brain abnormality; six months old: 
moderate brain atrophy sparing the posterior fossa 
 
phase: absence of any organization, rare spikes in 
both temporal regions; myoclonic seizures 
associated with EEG abnormalities (frequency 
range 0.25-1 Hz) 
 
6b 
 
first interictal: slow background activity, with slow 
waves, rare paroxysmal activity; interictal stormy 
phase: multifocal spikes low background activity, 
rare spindles; ictal: focal migrating discharges; 
interictal late phase: absence of any organization, 
rare spikes in both temporal regions; myoclonic 
seizures associated with EEG abnormalities 
(frequency range 0.25-1 Hz)  
na 
one month old: no structural brain abnormality; nine 
months old: global brain atrophy (grey matter) sparing the 
posterior fossa 
 
 
7a 
despite frequent seizures, several waking-sleep 
EEGs were within normal limits in the early 
months of the disease; a progressive slowing of the 
background activity and a gradual regression in the 
not present 
MRI at 6 months of age showed a diffuse delay in 
myelination and a thin corpus callosum; brain CT at 2 
years revealed diffuse atrophy with dilatation of the 
cerebral ventricles, subarachnoid space, and brain sulci 
phasic elements of sleep became evident in later 
records, as periods of waking and sleep became 
less distinctive, as well as rare and isolated small 
spikes and multiple spikes that were predominantly 
in the frontal and central regions; myoclonic 
activity on EMG present throughout all EEGs, 
more prominent during the waking state, becoming 
more abundant over time 
 
 
7b 
monotonous background activity composed of 
medium voltage and irregular slow waves within 
theta and delta ranges; amplitude was lower on the 
right hemisphere (left hemiplegia); there was 
ongoing phasic activity on the EMG channel, but 
no spikes were visible on the EEG channels; EMG 
was normal 
 
not present 
brain MRIs at the ages of 5 and 7 months normal; at 31 
months, shortly following left-sided hemiplegia, diffuse 
atrophy with right predominance, especially of right 
hippocampus; brain SPECT at that age disclosed areas of 
hypoperfusion in right frontal lower and middle, right 
mesial and lateral temporal, and left mesial temporal areas 
 7c 
early EEGs were reported to have generalized and 
multifocal multiple spikes as well as spike-waves 
discharges 
 
not present 
brain MRI at the ages of 14 and 37 months revealed 
progressive, diffuse cerebral and cerebellar atrophy with 
dilatation of the ventricles, sulci, and subarachnoid space 
8a 
always subnormal; at last follow-up (10 years), 
moderate and bilateral slowing of the background 
rhythm, 6-Hz theta and slow spikes at the vertex, as 
well as spike and wave activity in central regions 
not present 
at 11 months, normal brain MRI scan; at 6 years, after 
cardiac arrest, signal hyperintensity of the lentiform 
nuclei, moderate ventricular dilatation, and white matter 
rarefaction, on the T2 and FLAIR sequences 
8b 
mostly normal; 4 months: one recorded episode of 
myoclonia with very low amplitude spikes, mostly 
at the vertex, followed by hemispheric slow waves, 
predominating in central regions, intermixed with 
rare spikes and waves; 3.5 years: rare posterior 
slow spikes and increased amplitude of the 
posterior regions, during drowsiness 
not present at the age of 3 and 23 months, normal brain MRI 
9 
at 1.5 months, slow rhythms with transient burst-
suppression pattern; later abnormal background 
activity with delta slow waves, associated with 
spike and wave activity, more often with occipital 
localisation; last record showed very attenuated 
background activity 
not present 
global brain atrophy, in particular atrophy of the caudate 
and lenticular nuclei (8 months) 
10 
delta rhythm with multifocal paroxysms, no clear 
correlate of myoclonus (at 8 months) 
na brain atrophy (at 8 and 14 months) 
11 
first EEG normal (7 months); later, interictal: 
isolated or bursts of spikes over bifrontal regions 
and slow posterior waves; ictal: no paroxysmal 
anomalies during myoclonic jerks, but video 
recording with EEG jerk-locked back-averaging 
was  
suggestive of  cortical origin of myoclonus 
na 
at 3 and 7 years: progressive hemispheric (but not 
vermian) cerebellar atrophy with hyperintense signal of 
the cerebellar cortex and white matter, on T2 and FLAIR 
sequences 
12a 
no ictal activity captured; at 4 years, slightly slow 
occipital dominant rhythm of 7.5 Hz without focal 
findings 
not present normal (23 months) 
12b 
no ictal activity captured; at 10 years, dominant 
slow (7Hz) occipital rhythm, bilateral frontocentral 
rhythmic slow high-voltage activity 
not present normal (7 years) 
13 
normal at 4 months; very abnormal EEG at 6 
months with paroxysmal epileptiform discharges, 
bouts of intense crying considered ictal on EEG 
na 
elevated glutamine peak (MRI); 
cerebellar atrophy, volume loss in left frontal lobe, 
enlargement of temporal horns suggestive of bilateral 
hippocampal atrophy (CT) 
14 
interictal multifocal independent spike waves (at 13 
years) 
na 
right hippocampal sclerosis, bilateral cerebellar atrophy, 
hyperintense signal of the cerebellar cortex (at 9 years) 
15 
mostly normal ictal and interictal EEG, rare 
interictal epileptic discharges fronto-centrally; in 
focal status epilepticus, rare seizures patterns with 
repetitive fronto-central epileptic discharges 
not present normal 
16 
excessively rhythmic background activity over 
parasagittal electrodes and bursts of high-amplitude 
slow waves anteriorly 
na normal 
17a 
first interictal EEG recording (on first day of life) 
unremarkable despite frequent seizures; later ictal 
EEG showed generalized spike-wave and poly-
spike discharges with fronto-central predominance; 
on several video-EEGs with myoclonic jerks, no 
clear epileptiform discharges were recorded; 
progression to burst-suppression before death 
not present unremarkable (age 1 month and 3 months) 
17b 
first interictal EEG recording (on first day of life) 
unremarkable despite frequent seizures; later 
generalized spike-wave and multiple spike-wave 
discharges with fronto-central predominance, 
slowing of the baseline activity and multifocal 
spikes 
not present 
prominent fronto-temporal atrophy with widening of the 
subarachnoid spaces and Sylvian fissures (1 month) 
18 
no paroxysmal abnormalities until the age of 7 
years, then rare bilateral sharp-waves prevalent in 
the right temporo-occipital regions 
na 
wide cisterna magna, thin corpus callosum, mild signal 
hyperintensity in tegmental area (at 6 years) 
 
19 left frontal dominant spike and wave na 
thin cerebellar cortex, hyperintense signal on T2-imaging, 
and myelination delay - white matter damage 
20a na na normal 
20b na na 
punctate foci of increased T2 signal in right frontal region; 
increased FLAIR signal around occipital horn 
21 normal not present delayed myelination (at 33 months) 
22 normal not present normal (at 2.5 years) 
23a 
normal EEG at the age of 10 years 7 months; poor 
organization, generalized slowing, frequent 
multifocal epileptiform activity at the age of 11 
years 
na normal 
23b 
at the age of 10 months, severely abnormal 
background EEG, no evident epileptiform activity 
na 
normal initially; at the age of 17 months, after acute 
hypoxic episode, marked increase in ventricular and 
subarachnoid space, with decrease in grey and white 
matter, diffuse but with occipital predominance 
24 normal interictal na normal 
25 
 
poorly organised background with slow waves (age 
18 and 19 years) 
 
na 
 
hyperintense T2 signals in the cerebellar hemispheres, 
especially on the left 
 
26 na na normal cranial ultrasound after birth 
27 
excess of irregular slow wave activity, often of 
higher amplitude on the right, with occasional runs 
of more prominent slow wave activity over the 
right hemisphere, more marked posteriorly; no 
epileptiform activity recorded (age 7 months) 
not present 
bilateral cerebral atrophy, particularly of the frontal lobes 
with widening of the Sylvian fissures, significantly 
delayed myelination and thin corpus callosum (age 7 
months) 
28 
multifocal interictal epileptiform discharges (sharp 
waves, fast activity, spikes, polyspikes), more 
frequent in sleep, disorganised and slow 
na 
day 7: normal; day 56: increased T2 signal in left 
hippocampus, prominent extra-axial cerebrospinal fluid 
spaces 
background, between 6 weeks and 8 months of age; 
ictal: spasms and multiple types of focal seizures 
(right temporal, left temporal, midline-left central) 
were recorded 
 
29 
 
dominant symmetrical monomorphic theta activity 
associated with rare symmetrical alpha activity and 
bilateral occipital paroxysmal spike-and-wave 
activity on eye closure (eye closure sensitivity)e2 
(age 23 years) 
not present mild hypoplasia of the cerebellar vermis (age 23 years) 
30 
interictal: widespread slow activity with frequent 
sharp waves over mid-parietal and right parietal 
regions and independent brief episodes of repetitive 
spikes over both fronto-central regions; ictal: 
repetitive spikes over the left temporal leads 
na 
normal antenatal brain MRI; evidence of trigonocephaly 
due to premature fusion of the metopic suture; mild lack 
of white matter bulk with delayed myelination (age 4 
months) 
31 
at onset (6years) generalized slowing of 
background activity, reminiscent of encephalitis; 
not present normal (age 6 years and 7 years) 
na=data not available 
 
 
 
 
 
follow-up: multifocal spike-waves, bi-frontal 
sharp-waves, generalized sharp-waves 
 
32 
 
frequent epileptiform discharges, both hemispheres, 
frequently associated with eyelid jerks 
photic stimulation 
between 4 and 8Hz 
provoked increasing 
duration of 
generalised spike and 
slow waves without 
clinical 
accompaniments 
normal 
Table e-3. Family history, facial and cranial features, acral manifestations and neurological examination.  
Patient 
number 
Family history 
of epilepsy* 
DOORS 
syndrome 
Facial and cranial 
features 
Acral manifestations Other findings on neurological examination 
1a-h 
all siblings or 
double first 
cousins 
no none none none 
2 
older brother 
with epilepsy 
no none none none 
3 none no 
thick lips, everted 
lower lip 
none hypotonia, nystagmus, tongue fasciculations 
 
4 
 
consanguineous 
parents 
no none none 
ataxia, bilateral spasticity, supranuclear gaze 
palsy, dystonia, superimposed tremor, 
progressive deterioration of gait (see 
Supplementary Video 1) 
5a 
consanguineous 
parents, three 
no none none dysarthria and ataxia 
siblings (5b,c,d) 
and three first 
cousins 
5b 
consanguineous 
parents, three 
siblings (5a,c,d) 
and three first 
cousins 
no none none 
dysarthria and ataxia, jerky pursuit eye 
movement 
5c 
consanguineous 
parents, three 
siblings (5a,b,d) 
and three first 
cousins 
no none none 
jerky pursuit eye movement and mild 
dysarthria 
5d 
consanguineous 
parents, three 
siblings (5a,b,c) 
no none none 
ataxia, jerky pursuit eye movement and 
increased jaw jerk 
and three first 
cousins 
6a sister (6b) no 
acquired 
microcephaly 
na 
normal at the initial phase; loss of eye contact 
at 4 months, severe axial hypotonia, dystonic 
movements 
6b sister (6a) no 
acquired 
microcephaly 
na 
normal at the initial phase; axial hypotonia 
from 3 months, loss of eye contact at 4 
months, severe 
hypotonia at 4.5 months old 
 
7a 
four similarly 
affected 
relatives, all 
born to 
consanguineous 
parents 
no na na 
dystonic episodes (both focal and axial) from 
the second year of life; right-sided spastic 
hemiparesis as a consequence of a prolonged 
unilateral seizure evident at 18 months; axial 
hypotonia and spasticity in the extremities 
with asymmetrical pyramidal signs were 
detected at the age of 21 months; at the age of 
23 months opisthotonic posturing was 
predominant, and repetitive startle responses 
occurred, without habituation 
 
7b 
four similarly 
affected 
relatives, all 
born to 
consanguineous 
parents 
no na na 
at the age of 31 months, left- sided epilepsia 
partialis continua started, associated with a 
permanent hemiplegia; two months later, she 
was inattentive and only partly responsive to 
verbal stimuli; there was spastic hemiparesis 
and dystonia on the left side 
 
7c 
four similarly 
affected 
relatives, all 
born to 
consanguineous 
parents 
no na na 
at the age of 3 years, totally nonreactive to all 
environmental stimuli; generalized hypotonia 
with pyramidal signs and minor erratic 
myoclonia; pupils dilated, with no light 
response 
8a brother (8b) no 
acquired 
microcephaly; 
bulbous nasal tip, flat 
nasal root 
none 
at seizure onset (24 hours of life), global 
hypertonia and incessant crying; at last follow-
up (10 years), spastic tetraparesis, no verbal 
language 
8b brother (8a) no 
bulbous nasal tip, flat 
nasal root, down-
slanting palpebral 
fissures 
none 
at 3.5 years, he could walk with help and say 
10 words 
9 none no 
bulbar nose, flat 
nasal root 
none pyramidal tract signs 
10 no no microcephaly none none 
11 none no 
narrow forehead, 
thin upper lip, 
marked philtrum 
none mild ataxia, clumsiness and tremor 
12a sister (12b) no 
upslanting palpebral 
fissures, increased 
intercanthal distance 
none none 
12b sister (12a) no none none none 
13 none no 
microcephaly, 
widely spaced teeth 
none 
choreoatethoid movement, dystonia, 
hypotonia, spastic quadriplegia 
14 none no triangular face 
onychodystrophy in 4th 
and 5th toenail 
ataxia, hand tremor, progressive gait 
deterioration, no verbal language 
15 
paternal great 
uncle 
no 
relatively large round 
head, smaller right 
eye 
small hands and short fat 
fingers 
fine motor deficits, slight balance problems 
16 none no 
small head, large 
ears, narrow 
palpebral fissures, 
prominent nasal 
bridge, protruding 
clinodactyly of fourth and 
fifth toes 
unable to walk 
nasal tip, prominent 
incisors, 
microcephaly 
17a 
paternal 
grandmother, 
father’s half-
sister and 
brother (17b) 
no none none 
axial hypotonia, dyskinetic movements with 
upper limb dystonia 
17b 
paternal 
grandmother, 
father’s half-
sister and sister 
(17a) 
no 
acquired 
microcephaly 
none 
axial hypotonia, dyskinetic movements with 
upper limb dystonia 
18 
two cousins in 
paternal line 
with epilepsy 
no none none mild ataxia, severe hyperactivity 
19 none yes 
prominent eyelashes, 
thick eyebrows, 
narrow palpebral 
fissures, thick lower 
vermilion 
small nails all fingers and 
toes bilaterally, hand 
brachydactyly, 
triphalangeal thumb, long 
thumbs and halluces 
 
none 
20a 
brother with 
DOORS 
syndrome (20b) 
yes 
large central incisors, 
widely spaced teeth, 
delayed eruption of 
permanent teeth, 
sagittal 
craniosynostosis 
hand and foot 
abnormalities (involving 
nails and fingers/toes), 
hand brachydactyly, 
calcaneal deformity 
na 
20b 
brother with 
DOORS 
syndrome (20a) 
yes na 
hand and foot 
abnormalities (involving 
nails and fingers/toes), 
hand brachydactyly 
na 
21 na yes microcephaly 
hand and foot 
abnormalities (involving 
nails and fingers/toes), 
hand brachydactyly 
at 5 years, could say a few words, use sign 
language, broad-based gait 
22 
one sibling with 
epilepsy 
yes 
low anterior hairline, 
thick hair, narrow 
forehead, prominent 
eyelashes, 
synophrys, thick 
eyebrows, broad 
nasal bridge, stained 
teeth 
hand and foot 
abnormalities (involving 
nails and fingers/toes), 
hand brachydactyly, 
triphalangeal thumb, long 
thumbs and halluces, 
hypoplastic distal 
phalanx, fetal finger pads 
none 
23a 
brother with 
DOORS 
syndrome (23b) 
yes 
prominent nose and 
ears, widely spaced 
teeth, brachycephaly 
hand and foot 
abnormalities (involving 
nails and fingers/toes), 
hand brachydactyly 
none 
23b 
brother with 
DOORS 
syndrome (23a) 
yes 
prominent nose and 
ears, widely spaced 
teeth 
hand and foot 
abnormalities (involving 
nails and fingers/toes), 
hand brachydactyly 
hypotonia, absent eye contact 
24 mother yes 
microcephaly, 
bilateral epicanthus, 
thin upper lip, 
reverse dental 
articulation, 
moderate mid face 
retraction 
hand and foot 
abnormalities (involving 
nails and fingers/toes), 
hand brachydactyly 
hypotonia, ataxia 
25 none yes 
thick eyebrows, 
downward slant 
palpebral fissures, 
wide nasal bridge, 
hand brachydactyly, small 
5th finger with hypoplastic 
distal phalanx, small nails 
all fingers and toes 
none 
thick alae nasi, broad 
nasal bridge 
26 
similarly 
affected brother, 
who died at the 
age of 9 
months; 
consanguineous 
parents 
yes 
broad nasal tip, 
narrow palate, 
prominent and broad 
alveolar ridge, sparse 
eyebrows, long and 
prominent philtrum, 
thin upper lip, short 
lingual frenulum 
causing furrowing of 
the tongue, capillary 
hemangioma 
(glabella and at 
nose), mild 
bitemporal 
hand brachydactyly, 
triphalangeal thumb 
hypotonia 
narrowing, flat 
glabella, prominent 
occiput, parietal 
prominence, frontal 
bossing wide 
fontanelles 
27 none yes 
broad nasal tip, thick 
alae nasi, broad nasal 
bridge, broad and 
longish philtrum; 
thick lower 
vermillion, drooping 
lower lip, thick hair 
at 3 years and 7 
months, high arched 
hand brachydactyly, long 
halluces, small 5th finger, 
absent distal phalanx 5th 
finger; fetal finger pads; 
bilateral small nails all 
fingers/toes 
hypotonia, congenital 
palate, asymmetric 
brachycephaly 
28 father yes 
 
premature closure of 
fontanelle, coarse 
facial features 
 
absent toenail and end of 
the right second toe 
hypotonia, nystagmoid eye movements 
 
29 
 
none yes 
frontal bossing, 
sunken nasal bridge, 
low-implanted ears 
anonychia on the first and 
fifth finger of both hands 
and on all toes, presence 
of small dystrophic nails 
on the remaining fingers, 
absence of the distal 
phalanx of the fifth finger 
of both hands and 
hypoplasia of the distal 
parkinsonism with onset at 21 years (mixed 
resting-postural tremor and rigidity of the right 
arm and right-side bradykinesia; mild 
dysdiadochokinesia and reduced tendon 
reflexes 
phalanxes of the 
remaining fingers 
30 
one sibling 
affected 
prenatal 
(pregnancy 
terminated 
because of 
increased 
nuchal of 
5.1mm at 12/40) 
yes 
arched, fine 
eyebrows; bilateral 
pre-auricular tags, 
narrow ear canals; 
broad nasal bridge; 
cleft lip and 
alveolus; gum 
hypertrophy, bifid 
uvula; metopic 
ridging, leading to 
appearance of 
trigonocephaly, 
microcephaly 
absent distal phalanges of 
fingers from index to little 
in both hands, with 
hypoplastic distal phalanx 
of thumbs; in feet, absent 
distal phalanges all toes, 
with hypoplastic middle 
phalanges of little toes; 
stippling of tarsal bones; 
absent nails of all digits 
on hands and feet 
initially hypotonia, then developed hypertonia; 
no speech; unable to walk 
31 none no 
broad nasal bridge, 
high arched palate 
small toenails 
mild hypotonia, no focal neurological 
abnormality 
32 none no none na none 
na=data not available 
*There were seven similarly affected siblings (one in family 2, three in family 5, one in family 7, one in family 22 and one in family 27) 
that did not have DNA analysis and were not included in our analysis, but we presume they had the same mutation(s) as their siblings. 
We thus identified two more patients (one affected patient in family 7, and a sibling of patient #27) with myoclonic epilepsy and 
presumed TBC1D24 mutation. Overall, with these additional patients, clonic or myoclonic seizures were present in 32/55 (58%) of 
patients.
S2. Multi-organ involvement. 
The following non-DOORS patients had hearing loss: #17a (bilateral sensorineural 
hearing loss of 50 dB threshold), #17b (profound sensorineural deafness), #18 
(bilateral hypoacusia). There was family history of hearing loss in patients #16 
(brother) and #31 (hearing loss in maternal grandmother from childhood onwards, 
now nearly deaf). 
There was visual impairment in patients: #3 (nystagmus), #4 (nystagmus, visual 
decline), #6a (pre-terminal cortical blindness), #7c (bilateral optic atrophy and 
macular degeneration), #10 (no ocular pursuit, severe encephalopathy), #15 (+2 
dioptres in the left eye), #20a-b and 21 (all with myopia), #23a, #23b (post- 
asphyxia), #28 (cortical visual impairment), #30. 
Renal anomalies were present in two patients: #21 (nephrocalcinosis) and #27 
(hydronephrosis left kidney, prenatal diagnosis). 
Skeletal anomalies, other than acral manifestation, were found in patients: #4 
(bilateral cavovarus deformities; significant external tibial torsion; kyphotic posture), 
#6a-b, 13 and 30 (all with scoliosis).  
Cardiac anomalies were present in patients: #8a (at 6 years and 10 months, cardiac 
arrest of unknown cause), #20b (double outlet right ventricle), #23b (at 10 months, 
cardiac arrest of unknown cause), #28 (patent foramen ovale). 
Feeding difficulties were reported in patients: #4 (due to myoclonus), #6a-b (both 
with gastrostomy), #7a-c, #9 (enteral feeding), #10, #11 (only during episodes of 
facial myoclonus), #13 (naso-gastric tube from 3 years), #16, #17a (gastrostomy), 
#17b (naso-gastric tube), #20a-b, #23a-b, #28, #30 (naso-gastric tube from 4 months). 
Other co-morbidities were described in patients; #4(severe iron deficiency, severe 
constipation, drooling, cataplexy, neonatal jaundice), #7a-c (repeated episodes of 
common infections), #8a (self-injurious behaviour and sleep disturbance), #13 
(paracentric inversion (1)(q42.13q44) on karyotype; Raynaud phenomenon in lower 
extremities), #16 (motor neuropathy), #19 (autism spectrum disorder), #24 
(hyperactivity, sleep disorder), #25 (hypothyroidism), #27 (cryptorchidism, frequent 
respiratory tract infections), #28 (periods of irregular breathing in wake; irritability; 
poor sleep), #29 (supernumerary nipple; asymptomatic peripheral polyneuropathy, 
mixed axonal-demyelinating sensorimotor; psychotic symptoms). 
Urine 2-oxoglutarate was elevated in patients #4, #15, #20b, #25, #26, #27, #28, #29. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table e-4. Coding DNA position and ExAC allele count of the mutations identified in TBC1D24. Longest isoform, harbouring 
exon 3, is used (isoform 1, NM_001199107.1, hg19). 
Patient 
number 
Origin Alleles, DNA (protein) 
ExAC allele count 
(version 0.3, accessed 
18.10.15) 
Reference 
1a-h Italy c.439G>C (p.Asp147His)/ c.1544C>T(Ala515Val) 
not present/ 
3/103786 
de Falco et al., 
2001 
2 USA c.919A>G(p.Asn307Asp)/ c.845C>G(p.Pro282Arg) 
not present/ 
21/120442 
unreported 
3 Germany c.686T>C(p.Phe229Ser)/ c.1499C>T(p.Ala500Val) 
not present/ 
not present 
unreported 
4 Afghanistan c.1079G>T(p.Arg360Leu)/ c.1079G>T(p.Arg360Leu) 1 / 84934 
Muona et al., 
2014 
5a-d 
Arab-Israeli 
family 
c.751T>C(p.Phe251Leu)/ c.751T>C(p.Phe251Leu) not present 
Corbett et al., 
2010 
6a-b France c.468C>A(p.Cys156*)/ c.686T>C (p.Phe229Ser) 
not present/ 
not present 
Milh et al., 2013 
7a-c Turkey 
c.969_970delGT (p. Ser324Thrfs*3)/ c.969_970delGT 
(p. Ser324Thrfs*3) 
not present 
Güven et al., 
2013 
8a-b France c.457G>A p.Glu153Lys)/ c.457G>A p.Glu153Lys) 10 / 118188 
Poulat et al., 
2015 
9 France c.277C>T(p.Pro93Ser)/ c.1544C>T(p.Ala515Val) 
not present/ 
3 / 103786 
unreported 
10 Italy c.32A>G(p.Asp11Gly)/ c.32A>G(p.Asp11Gly) not present unreported 
11 France c.809G>A(p.Arg270His)/ c.809G>A(p.Arg270His) 2 / 120532 
Doummar et al, 
2015 
12a-b USA 
c.115G>C(p.Ala39Pro)/ c.1661_1667del(p.Gln 
554Leu fs*12) 
not present/ 
not present 
Cardon & 
Holder, 2015 
13 USA c.731C>T(p.Ala244Val)/ c.731C>T(p.Ala244Val) 2 / 120538 unreported 
14 Chile 
c.679C>T(p.Arg227Trp)/ c.1544C>T(p.Ala515Val) 2 / 120400/ 
3 / 103786 
unreported 
15 Germany 
c.533C>G(p.Ser178Trp)/ c.680G>A(p.Arg227Gln) not present/ 
3 / 120392 
unreported 
16 Pakistan c.957G>C(p.Lys319Asn)/ c.957G>C(p.Lys319Asn) not present unreported 
17a-b Slovenia 
c.1008delT(p.His336Glnfs*12)/ 
c.32A>G(p.Asp11Gly) 
not present/ 
not present 
Gnidovec 
Stražišar et al., 
2015 
18 Italy c.619C>T(p.Gln207*)/ c.1530A>G(splice-site) 
3 / 120282/ 
2 / 95480 
unreported 
19 Japan 
c.724C>T(p.Arg242Cys)/ c.118C>T(p.Arg40Cys) 1 / 120504/ 
2 / 119952 
Campeau et al., 
2014a 
20a-b USA 
c.724C>T(p.Arg242Cys)/ c.724C>T(p.Arg242Cys) 
1 / 120504 
Campeau et al., 
2014a 
21 Germany 
c.1008delT(p.His336Glnfs*12)/ c.1206+5G>A(spice-
site) 
not present/ 
not present 
Campeau et al., 
2014a 
22 India 
c.724C>T(p.Arg242Cys)/ c.724C>T(p.Arg242Cys) 
1 / 120504 
Campeau et al., 
2014a 
23a-b Chile 
c.58C>T(p.Gln20*)/ c.724C>T(p.Arg242Cys) 10 / 120240/ 
1 / 120504 
Campeau et al., 
2014a 
24 France 
c.1008delT(p.His336Glnfs*12)/ not identified 
not present 
Campeau et al., 
2014a 
25 Brazil 
c.724C>T(p.Arg242Cys)/ c.724C>T(p.Arg242Cys) 
1 / 120504 
Campeau et al., 
2014a 
26 Turkey 
c.119G>T(p.Arg40Leu)/ c.119G>T(p.Arg40Leu) 
not present 
Campeau et al., 
2014a 
27 UK 
c.328G>A(p.Gly110Ser)/ c.999G>T(p.Leu333Phe) 1 / 118678/ 
not present 
Campeau et al., 
2014a 
28 Australia 
c.1460dupA(p.His487Glnfs*71)/c.313T>C(p.Cys105A
rg) 
not present/ 
not present 
unreported 
29 Italy 
c.619C>T(p.Gln207*)/ c.1126G>C(p.Gly376Arg) 3 / 120282/ 
not present 
Bilo et al., 2014 
30 Afghanistan 
c.1384del(p.Glu462Serfs*61)/ 
c.1384del(p.Glu462Serfs*61) 
not present unreported 
31 Germany 
c.179G>A(p.Arg60Gln)/ c.702G>A(p.=); in cis 26 / 119704/ 
23 / 120454 
unreported 
32 UK 
16p13.3 duplication of 407 Kb including, but not 
interrupting, TBC1D24 (2,481,289-2,888,632)x3 
/ unreported 
All mutations were validated by Sanger sequencing. Individuals with letters a-h after the number are part of families. 
*The histidine (His) at position 336 is substituted by a glutamine (Gln), which is followed by a frameshifted protein sequence (fs) ending 
with a termination codon (Ter) after 12 non-native aminoacids. 
? In patient #24, no mutation was identified in the second allele. 
The ExAC frequency was not matched for ethnicity.  
Patients #31 and #32 were not included in the final analysis because a clear association of the clinical phenotype with changes in 
TBC1D24 could not be established.
 
 
 
 
S3. Genotype-phenotype correlation 
Below, details are provided about the most recurrent mutations, presented in order of 
frequency. 
 
The most common recurrent mutation was chr16:2546873C>T transition (hg19 numbering 
used), resulting in an arginine to cysteine (p.Arg242Cys) substitution in the TBC domain, 
present in seven individuals in five unrelated families of different national origins (Japan, 
USA, India, Chile and Brazil), all with DOORS syndrome.e3 Four individuals were 
homozygous (#20a-b; #22; #25) for this missense variant, and three were compound 
heterozygous (#19; #23a-b). Three patients had different epilepsy types and ‘adequate’ 
seizure control; one patient (#25) was seizure-free on phenytoin and clobazam. Patients #19, 
#22 and #23b were drug-resistant. Patient #23a, after initial satisfactory seizure control on 
phenobarbital and clobazam, at the age of 11.5 years showed clinical deterioration with daily 
seizures and encephalopathy. He was treated with a combination of clobazam, lamotrigine 
and sodium valproate, with gradual resolution of the encephalopathy, after which he 
continued to have very frequent myoclonic movements (not rhythmic, rather erratic, 
sometimes ameliorating with postural changes) of the arms, sometimes also affecting the 
legs, without impairment of awareness (see Supplemental Video 2). The degree of 
intellectual disability varied from mild to severe. The interictal EEG showed different 
patterns: focal abnormalities (#19), normal (#22 and initially for #23a), poor organization, 
generalised slowing and multifocal abnormalities (later #23a), poor organization without 
epileptiform activity (#23b), and poor organization and slow waves (#25).  
 
The frameshift mutation chr16:2548263delT (p.His336Glnfs*12) was identified as part of 
compound heterozygosity in four patients (#17a-b; #21 and #24; in the last patient no 
mutation was detected in the other allele). This mutation was not in a known functional 
domain. All these four patients had severe drug-resistant epilepsy with early seizure onset 
(ranging from 45 minutes after birth to three months of age) and multiple seizure types. Three 
have microcephaly and/or hypotonia. All have profound bilateral sensorineural hearing loss. 
These patients are two unrelated patients with DOORS syndrome and one sibling pair with 
early-onset epileptic encephalopathy and early death.  
 
The heterozygous missense chr16:2550823C>T (p.Ala515Val) mutation, in the TLDc 
domain, was present in the eight members (#1a-h) of the Italian family with familial infantile 
myoclonic epilepsy, in a French patient with early-onset epileptic encephalopathy (#9) and in 
a Chilean patient (#14) with multifocal epilepsy. The epilepsy type and outcome were quite 
different, varying from myoclonic or tonic-clonic seizures, well-controlled on one or no 
antiepileptic medication (patients #1a-h), to myoclonic, clonic, focal or tonic-clonic seizures 
with focal onset, not responsive to antiepileptic treatment (patients #9 and #14). Patients #1a-
h had no signs of cognitive impairment and a normal neurological examination, while 
patients #9 and #14 had severe to profound intellectual disability and neurological 
abnormalities. Functional experiments suggest that this variant causes a loss of function of 
TBC1D24 protein.e4  
 
The heterozygous missense chr16:2546835T>C (p.Phe229Ser) mutation, in the TBC domain, 
was found in three individuals (#3; #6a-b), one with infantile myoclonic epilepsy and two 
siblings with familial epilepsy of infancy with migrating focal seizures (EIMFS). Functional 
assay revealed loss of ARF6 binding.e5 Clonic or myoclonic seizures, and hypotonia, were 
reported in all three patients. Neuroimaging was initially unremarkable, but in the two 
siblings later showed supratentorial brain atrophy in the two siblings. The two siblings had a 
more severe phenotype and early death. 
 
The missense mutation chr16:2546181A>G (p.Asp11Gly) is not in a known functional 
domain, and was detected in three individuals (#10; #17a-b), all with early-onset epileptic 
encephalopathy. Of these, two were a sibling pair who had the mutation as part of compound 
heterozygosity in combination with the above-described frameshift mutation 
chr16:2548263delT, while the other individual was homozygous. All three patients had drug-
resistant epilepsy, predominantly myoclonic seizures, and severe intellectual disability. EEG 
showed multifocal epileptiform activity. Brain MRI scan (all performed between 1 to 16 
months of age) revealed brain atrophy in two patients (#10, #17b) and was normal in one 
other (#17a). Microcephaly was reported in patients #10 and #17b. The two siblings #17a and 
#17b both had profound hearing loss and died early. 
 
Another recurrent heterozygous mutation in the TBC domain was the transition 
chr16:2546768C>T, leading to a premature termination codon, p.Gln207*. This mutation was 
found in two unrelated patients (#18; #29), one with generalised epilepsy, DOORS syndrome 
and parkinsonisme6 and the other with infantile myoclonic epilepsy. Both patients were drug-
resistant, with tonic-clonic seizures. Both had bilateral hypoacusia/deafness, but patient #18 
did not have onychodystrophy or osteodystrophy and was therefore not classified as DOORS 
syndrome. 
 
We report two additional patients (#31, #32) with variants in TBC1D24 of uncertain 
significance for the clinical phenotype (Tables e1-4). Patient #31 has drug-resistant 
unclassified epilepsy and some facial features (broad nasal bridge, high arched palate): two 
single nucleotide variants of uncertain significance of TBC1D24 were identified on the 
maternal allele (chr16:2546328G>A; chr16:2546851G>A, non-coding). Patient #32 has 
severe epilepsy with myoclonic atonic seizures and a heterozygous 16p13.3 duplication of 
407 Kb including TBC1D24, identified by array-CGH. The clinical relevance of this copy 
number variant is uncertain, as 22 genes, including TBC1D24, reside in this interval. 
Nonetheless, it is worth noting here that overexpression of TBC1D24 resulted in a marked 
increase in neurite length and arborisation in vitro,e4,e7 indicating a possible adverse effect of 
gene duplication. 
 
The homozygous mutation p.Glu153Lys, in the two siblings with familial infantile myoclonic 
epilepsy without evidence of hearing impairment (#8a-b), was recently identified as part of 
compound heterozygosity in a Moroccan family with recessive non-syndromic hearing loss.e8 
None of the other six TBC1D24 mutations previously identified in families with non-syndromic 
hearing loss (p.Asp70Tyr; p.Ser178Leu; p.Arg214His; p.Lys266Asn; p.Arg293Pro; 
p.Val445Val.fs32)e8-11 was present in our cohort. We note that two individuals in one of the 
families with recessive non-syndromic hearing loss due to p.Asp70Tyr mutation have a history 
of seizures, though the authors suggest that this association is coincidentale10. 
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